Biocon

Businesses
5 key growth verticals with the aim to deliver sustainable
long term value for patients, partners, healthcare
systems across the globe.
3 businesses
1. Custom research (Syngene)
2. Clinical development (Clinigene)
3. Biopharmaceuticals (Biocon)

(the Holding Company)

Bangalore Subsidiary

Bangalore Subsidiary

Bangalore Subsidiary

Malaysia Subsidiary

Switzerland
Subsidiary

Abu Dhabi
Joint venture
company

Subsidiary Companies
1. Syngene International Limitedis a custom research
organization offering synthetic chemistry and molecular
biology services for early stage drug discovery and
development.
2. Biocon Pharma Limited (BPL)began as a joint venture
with CIMAB to develop and market a range of monoclonal
antibodies and cancer vaccines.
3. Biocon Research Limited(BRL)is a wholly owned
subsidiary set up to undertake discovery and development
research work in biologics, antibody molecules and proteins.

Subsidiary Companies
4. NeoBiocon FZ LLCis a research and marketing
pharmaceutical company based in Abu Dhabi.
5. Biocon SAis a wholly owned subsidiary in Switzerland
primarily engaged in the development and commercialization
of biopharmaceuticals across the globe. Clinical Development
of Insulin is currently ongoing in the European region.
6. Biocon SDN. BHD. is a wholly owned subsidiary in Malaysia
to set up a state of the art manufacturing facility at BioXcell a
biotechnology park promoted by the Government of Malaysia.

Vision
To enhance global healthcare through innovative and affordable
biopharmaceuticals for patients, partners and healthcare
systems across the globe

Mission
To be an integrated biotechnology enterprise of global
distinction.
Essential to this mission is excellence in:
- Intellectual asset creation through discovery, research and
development
- State-of-the-art manufacturing capabilities
- Internationally benchmarked quality and regulatory systems
- New medical insight through disease specificclinical research
- Customer relationship through outstanding products and
services
- Human resource development through training , mentoring
and empowering
- Management of research and business partnerships

Values
Integrity and Ethical Behaviour
Performance driven work culture
Value Creation through Innovation & Differentiation
Quality through Compliance & Best Practices
Collaboration, Team Work & Mutual Respect

Strategic Alliance
BIOCON BRISTOL-MYERS SQUIBB: 2012
Biocon entered into an option agreement with Bristol-Myers
Squibb for Biocon's IN-105, an oral insulin drug candidate
Biocon to continue development of IN-105
Bristol-Myers Squibb will have an exclusive option to further
develop and commercialize IN-105

History
November
29,1978

1979

Biocons Founding
Day

Biocon is the first Indian

company to
manufacture and export
enzymes to USA and
Europe

2000

2001

Biocon commissions its first fully

automated submerged
fermentation plant to produce
specialty pharmaceuticals

Biocon becomes the first Indian

company to be approved by US
FDA for the manufacture of
lovastatin, a cholesterol-lowering
molecule

Biocon establishes Clinigene,

India's first Clinical Research
Organisation (CRO) to pursue
clinical research and development

2006
Biocon inaugurates Biocon
Biopharmaceuticals, India's largest
multi-product Biologics facility at
Biocon Park

Biocon's proprietary bioreactor,

PlaFractor is granted a US 2001
and world-wide patent

1989
Unilever plc. acquires Biocon
Biochemicals Ltd. in Ireland and
merges it with its subsidiary,
Quest International
Biocon is the first Indian biotech
company to receive US funding for
proprietary technologies

1993
Biocon's R&D and manufacturing
facilities receive ISO 9001
certification from RWTUV,
Germany

2004
2003
Biocon is the first company
worldwide to develop human
insulin on a Pichia expression
system

Biocon creates a buzz in the stock

market in March 2004 with its
hugely successful IPO. Day 1 on
the bourses closes with a market
value of $1.11 billion, making
Biocon only the second Indian
company to cross the $1 billion
mark on the first day of listing.

Biosimilars therapy areas - cancer, diabetes and rheumatoid

arthritis
Key products of Biosimilars portfolio are Recombinant
Human Insulin (rh-Insulin), Insulin Analogs and
Monoclonal Antibodies (MAbs)
Branded Formulations
Present in the chronic disease segment in India.
5 therapeutic segments: Metabolics, Oncotherapeutics,
Nephrology, Comprehensive Care and
Immunotherapeutics
Small Molecules
APIs